The Human Variable 

CRISPR²™ (CRISPR Readiness Index, Stabilization, Personalized Recovery) introduces a state-dependent framework for gene editing in complex chronic disease. Unlike conventional models that assume biological stability, CRISPR² integrates patient readiness, environmental exposure, temporal symptom dynamics, and recovery conditions to guide when and how intervention occurs. This approach expands therapeutic reach across severity levels, improves interpretation of outcomes in vari

Stage Zero™ defines the preclinical phase where immune and autonomic instability is already active but not yet captured by traditional diagnostics. By identifying structured symptom patterns, timing-based responses, and multi-system disruption, this framework enables earlier recognition of disease activity across conditions such as Long COVID, ME/CFS, POTS, and autoimmune disorders. Rather than waiting for diagnostic thresholds, Stage Zero™ introduces a trajectory-based model

A field guide for designing Lyme disease clinical trials that work. Learn how to improve outcomes using adaptive design, co-infection stratification, digital biomarkers, and CYNAERA’s stabilization-first framework.

Personalized CRISPR Remission™ for ME/CFS explores customized, individualized gene-editing strategies based on immune state, environmental factors, and neuroimmune instability to enable state-dependent remission in infection-associated chronic conditions. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system condition. Personalized CRISPR Remission™ for MECFS is not limited to one editing event or one delivery paradigm.

A new framework for disease prevalence estimation, the Diagnostic Multiplier™ (DM™) adjusts for underdiagnosis, diagnostic variability, and environmental exposure across conditions.

State-dependent oral CRISPR delivery framework modeling uptake, EBV targeting, and gene editing efficiency. Explores how immune state, environmental burden, and physiology determine real-world therapeutic success.